IP Library Granted Patent US 9,102,762
Granted Patent B2
US 9,102,762 · App. 13/349,980 · Granted Aug 11, 2015

Virus filtration of liquid factor VII compositions

Inventors: Jesper Christensen (Gentofte, DK); Erik Halkjær (Copenhagen N, DK); Turid Preuss (Smørum, DK); Thomas Budde Hansen (Copenhagen N, DK); Lene Vædele Madsen Tomoda (Lyngby, DK); Nina Johansen (Rødovre, DK)
Assignee: Novo Nordisk Healthcare AG
C07K14/745C12N7/00C12N9/6437C12Y304/21021C12N2740/13063
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,102,762
App. No.
13/349,980
Granted
Aug 11, 2015
Kind
B2
Abstract

The present invention relates to a novel method for improving the viral safety of liquid Factor VII compositions, in particular those comprising active Factor VII polypeptides (a Factor VIIa polypeptide).

Claims (15)

1. A method for removing viruses from a liquid composition of recombinant Factor VII comprising one or more Factor VII polypeptides having a concentration in the range of 0.01 to 5 mg/mL, the method comprising subjecting the liquid composition to nanofiltration using a nanofilter having a pore size of 80 nm or less, wherein 50-100% of the Factor VII polypeptides in the composition subjected to the nanofilter are in an activated form (FVIIa) prior to nanofiltration.

2. The method according to claim 1 , wherein the liquid composition has a pH of in the range of 7.0-9.5.

3. The method according to claim 2 , wherein the pH is in the range of 8.3-8.7.

4. The method according to claim 1 , wherein the pore size of the nanofilter is 50 nm or less.

5. The method according to claim 1 , wherein the membrane of the nanofilter is manufactured from one or more materials selected from the group consisting of: cuprammonium regenerated cellulose, hydrophilic polyvinylidene fluoride (PVDF), composite PVDF, surface modified PVDF, and polyether sulfone.

6. The method according to claim 1 , wherein the pore size of the nanofilter is in the range of 10-30 nm.

7. The method according to claim 1 , wherein the liquid Factor VII composition is obtained from a cell culture supernatant.

8. The method according to claim 1 , wherein the liquid composition is serum-free.

9. The method according to claim 1 , wherein the Factor VII polypeptide(s) is/are produced by cell culture in the presence of bovine or foetal calf serum.

10. The method according to claim 1 , wherein the Factor VII polypeptide(s) is/are produced by cell culture in Chinese Hamster Ovary (CHO) cells in a medium free from any components of animal origin.

11. The method according to claim 1 , wherein the concentration of the Factor VII polypeptide(s) in the liquid composition is in the range of 0.05-2.0 mg/mL.

12. A method for removing viruses from a liquid composition of recombinant Factor VII comprising one or more Factor VII polypeptides having a concentration in the range of 0.01 to 5 mg/mL, wherein 50-100% of the Factor VII polypeptides in the composition are in an activated form (FVIIa) prior to nanofiltration, the method comprising the steps of (i) combining the composition with a detergent, and (ii) subjecting the solution to nanofiltration using a nanofilter having a pore size of 80 nm or less.

13. The method of claim 1 , wherein 70-100% of the Factor VII polypeptides in the composition subjected to the nanofilter are the activated form of Factor VII.

14. The method of claim 1 , wherein 80-100% of the Factor VII polypeptides in the composition subjected to the nanofilter are the activated form of Factor VII.

15. A method for removing viruses from a liquid composition of recombinant Factor VII comprising one or more Factor VII polypeptides having a concentration in the range of 0.01 to 5 mg/mL, the method comprising subjecting the liquid composition to nanofiltration using a nanofilter having a pore size of 50 nm or less, wherein 50-100% of the Factor VII polypeptides in the composition subjected to the nanofilter are in an activated form (FVIIa) prior to nanofiltration.

Assignments (1)
CHANGE OF ADDRESS OF ASSIGNEE Recorded Nov 15, 2021
From: NOVO NORDISK HEALTHCARE A/G
To: NOVO NORDISK HEALTHCARE AG
Reel/Frame 058122/0546 →
Priority Claims (1)
DK 2003 01775 · Dec 1, 2003 · national
Continuity (5)
Continuation 12173475 · Jul 15, 2008
Continuation 11439828 · May 23, 2006
Continuation PCTDK2004053206 · Dec 1, 2004
Provisional Application 60528763 · Dec 11, 2003
Related Publication 20120115204A1 · May 10, 2012